EcoR1 Capital’s Sage Therapeutics SAGE Stock Holding History

EcoR1 Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-940,636	Closed	-$40M	–	95
2021 Q4	$40M	Buy	+940,636	New	+$39.4M	1.28%	22
2020 Q1	–	Sell	-173,364	Closed	-$12.5M	–	58
2019 Q4	$12.5M	Buy	+173,364	New	+$21.3M	1.13%	22
2015 Q2	–	Sell	-112,455	Closed	-$5.65M	–	28
2015 Q1	$5.65M	Sell	112,455 -378,589	-77%	-$16.3M	1.88%	16
2014 Q4	$9.07M	Buy	+491,044	New	+$18.3M	4.59%	10

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital's SAGE Position: Q1 2022 in Review

EcoR1 Capital sold out of Sage Therapeutics (SAGE) in Q1 2022, closing a stake of 940,636 shares — an estimated $40M sold.

EcoR1 Capital first reported a position in SAGE in Q4 2014 and held it in 4 quarters. The position peaked at $40M in Q4 2021. 212 funds tracked by Wall St. Rank hold SAGE as of Q1 2022.

EcoR1 Capital reported no remaining Sage Therapeutics position as of Q1 2022 after selling out during the quarter.
EcoR1 Capital sold 940,636 Sage Therapeutics shares in Q1 2022, an estimated $40M.
EcoR1 Capital first reported a position in Sage Therapeutics in Q4 2014 and held it in 4 quarters.
EcoR1 Capital's Sage Therapeutics position peaked at $40M in Q4 2021.
212 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2022.

Based on EcoR1 Capital's 13F filing for Q1 2022, filed 16 May 2022.